Can I read Antibodies against JC virus and stratification of the progressive multifocal leukoencephalopathy risk in patients on EtoBox?

Antibodies against JC virus and stratification of the progressive multifocal leukoencephalopathy risk in patients by MUDr.Dana Horáková, Ph.D., prof.MUDr.Eva Havrdová, CSc. is a scholarly article available to read on EtoBox.

What is Antibodies against JC virus and stratification of the progressive multifocal leukoencephalopathy risk in patients about?

with multiple sclerosis. Recommendations for a new diagnostic test – STRATIFY JCVTM Tysabri (natalizumab) is a monoclonal antibody proved to be very effective in a treatment of multiple sclerosis (MS). The drug has shown a very good tolerability, except in a rare viral infection, progressive multifocal leukoencephalopathy (PML). The common JCvirus is a causative agent of PML. Its seroprevalence in human population ranges between 50 and 60 %. It was reported for the first time in the year 2005 in two patients with MS. Until June 1, 2011, 133 cases of PML have been reported from the cohort of approximately 84 thousand patients treated with Tysabri all over the world. The paper summarizes current knowledge of the risk factors related to PML – significantly higher risks seem to be in a subgroup of patients with 1) persistence of JC virus in the patient’s body (ELISA diagnostic set for JCV with high sensitivity and specificity has been available in all MS centers since May 2011) in combination with 2) previous immunosuppressive therapy and 3) duration of the therapeutic exposition to Tysabri exceeding 24 months. The increased clinical supervision as well as other current PML-related saf

Author

MUDr.Dana Horáková, Ph.D., prof.MUDr.Eva Havrdová, CSc.

Published

2011